Ravi Rajaram, MD, MSc, Jennifer L

Slides:

Advertisements

Similar presentations

Elizabeth A. David, MD, David T

Advertisements

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Thomas J. Birdas, MD, Richard P. M

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

The Society of Thoracic Surgeons Lung Cancer Resection Risk Model: Higher Quality Data and Superior Outcomes Felix G. Fernandez, MD, MS, Andrzej S. Kosinski,

Joshua E. Rosen, BASc, Hari B

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Benson Bertheau Roe, MD, July 7, 1918–August 6, 2012

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Surgical Resection of a Giant Coronary Aneurysm

Katy A. Marino, MD, Jennifer L. Sullivan, MD, Benny Weksler, MD

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes Damien J.

Who Do You Say You Are? The Annals of Thoracic Surgery

Surgical Considerations for the Management and Resection of Esophageal Gastrointestinal Stromal Tumors Matthew G. Blum, MD, Karl Y. Bilimoria, MD, Jeffrey.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Use of Amiodarone After Major Lung Resection

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Yang Zhang, MD, Haiquan Chen, MD, PhD

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

Kathryn E. Engelhardt, MD, Malcolm M. DeCamp, MD, Anthony D

Pulmonary Resection for Lung Cancer in Octogenarians

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,

Specialty Training and Mortality After Esophageal Cancer Resection

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

The Impact of Computed Tomographic Screening for Lung Cancer on the Thoracic Surgery Workforce Janet P. Edwards, MD, MPH, Indraneel Datta, MD, MSc (HEPM),

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Matthew J. Schuchert, MD, Omar Awais, DO, Ghulam Abbas, MD, Zachary D

Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience Inderpal S. Sarkaria,

Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

The Impact of New Technology on Cardiothoracic Surgical Practice

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer Ravi Rajaram, MD, MSc, Jennifer L. Paruch, MD, MS, Sanjay Mohanty, MD, MS, Jane L. Holl, MD, MPH, Karl Y. Bilimoria, MD, MS, Clifford Y. Ko, MD, MSHS, David P. Winchester, MD, Jyoti D. Patel, MD, Malcolm M. DeCamp, MD The Annals of Thoracic Surgery Volume 101, Issue 2, Pages 533-540 (February 2016) DOI: 10.1016/j.athoracsur.2015.08.077 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Graph shows the proportion of patients with stage IB disease who received neoadjuvant chemotherapy (blue), adjuvant chemotherapy (green), or surgical resection only (orange) over time. The Annals of Thoracic Surgery 2016 101, 533-540DOI: (10.1016/j.athoracsur.2015.08.077) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Graph shows the proportion of patients with stage II to IIIA disease who received neoadjuvant chemotherapy (blue), adjuvant chemotherapy (green), or surgical resection only (orange) over time. The Annals of Thoracic Surgery 2016 101, 533-540DOI: (10.1016/j.athoracsur.2015.08.077) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions